Bicara Therapeutics (BCAX) experienced a sharp decline in the pre-market session on Friday, with its stock plummeting 7.29%. This significant drop comes in the wake of a target price reduction by H.C. Wainwright, a prominent investment bank and research firm.

H.C. Wainwright revised its target price for Bicara Therapeutics, lowering it from $44 to $41. This adjustment represents a decrease of approximately 6.8% in the expected value of the stock. While the reasons behind the target price cut were not explicitly stated in the available information, such revisions often reflect changes in a company's financial outlook, market conditions, or specific challenges facing the business.

The market's strong negative reaction to this news underscores the influence that analyst recommendations and price targets can have on investor sentiment, particularly for biotechnology companies like Bicara Therapeutics. As investors digest this new information, it remains to be seen how the stock will perform throughout the trading day and in the coming weeks.